FAIRplus Annual General Assembly

The first FAIRplus Annual General Assembly meeting will take place on 30-31 January 2020 in Hinxton, Cambridge, UK.

The meeting will bring together our 22 project partners from EFPIA, academia and SMEs with our Scientific and Industry Advisory Board and Ethics Advisory Board, in order to review the project achievements and activities so far and discuss plans for the next two and a half years and beyond. We look forward to welcoming you there!

Overview of day 1:
09:00-12:00 SIAB, EAB, WPL (meetings by invitation only)
12:00-13:00 Lunch / General Assembly Registration
13:00-17:50 General Assembly - WP breakout sessions
19:00-21:00 Conference Dinner

Overview of day 2:
09:00-13:20 General Assembly

Location

The location of this event will be:

The Kendrew Lecture Theatre, South Building
Wellcome Genome Campus
Hinxton, Cambridgeshire
CB10 1SD, UK

More details on how to find us including travelling by car or train can be found on our website.

Accommodation

On campus Conference Centre - A limited number of bedrooms have been booked at the Conference Centre on campus. These are issued on a first-come, first-served basis. The cost is £102 with payment due on check out. To book, please telephone: 01223 495000 quoting REFERENCE NO: 17427

Please note, the Conference Centre can only guarantee these rooms till 1 December.

Off campus Holiday Inn - A limited number of bedrooms have been booked at the Holiday Inn, Whittelsford. These are issued on a first-come, first-served basis. The cost is £120 with payment due on check out. To book, please telephone: 01223 497070 quoting REFERENCE NO: ELI

Details of the full draft agenda can be accessed on the FAIRplus google drive.

Registration deadline: Friday 10 January 2020

REMINDER: We are hosting our first FAIRplus Innovation and SME Forum on Wednesday 29 January. It is free to attend and takes place at the same location but registation must be completed seperately. Please click here for the resgistration.

FAIRplus has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 802750. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA Companies. This communication reflects the views of the authors and neither IMI nor the European Union, EFPIA or any Associated Partners are liable for any use that may be made of the information contained herein.